145 related articles for article (PubMed ID: 36961119)
1. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States.
Li P; Benson C; Geng Z; Seo S; Patel C; Doshi JA
J Med Econ; 2023; 26(1):525-536. PubMed ID: 36961119
[TBL] [Abstract][Full Text] [Related]
2. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
4. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
Mahabaleshwarkar R; Lin D; Joshi K; Fishman J; Blair T; Hetherington T; Palmer P; Patel C; Krull C; Tcheremissine OV
J Ment Health Policy Econ; 2021 Jun; 24(2):47-59. PubMed ID: 34151777
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
7. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
9. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
11. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
Patel C; Pilon D; Morrison L; Holiday C; Lafeuille MH; Lefebvre P; Benson C
Curr Med Res Opin; 2023 Aug; 39(8):1157-1166. PubMed ID: 37461233
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
Fu AZ; Pesa JA; Lakey S; Benson C
BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
14. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
15. Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs.
Patel C; Huang A; Wang L; Paliwal Y; Joshi K
Adv Ther; 2022 Mar; 39(3):1199-1214. PubMed ID: 34994955
[TBL] [Abstract][Full Text] [Related]
16. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
17. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
18. Inpatient Utilization and Costs for Medicare Fee-for-Service Beneficiaries with Heart Failure.
Fitch K; Pelizzari PM; Pyenson B
Am Health Drug Benefits; 2016 Apr; 9(2):96-104. PubMed ID: 27182428
[TBL] [Abstract][Full Text] [Related]
19. Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
Pesa J; Liu Z; Fu AZ; Campbell AK; Grucza R
Schizophr Res; 2023 Nov; 261():170-177. PubMed ID: 37778124
[TBL] [Abstract][Full Text] [Related]
20. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.
Munday J; Greene M; Chang E; Hartry A; Yan T; Broder MS
Curr Med Res Opin; 2019 Jul; 35(7):1231-1239. PubMed ID: 30649965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
